(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 10.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.68%.
United Therapeutics's revenue in 2026 is $3,169,800,000.On average, 17 Wall Street analysts forecast UTHR's revenue for 2026 to be $140,286,452,565, with the lowest UTHR revenue forecast at $130,396,363,776, and the highest UTHR revenue forecast at $149,454,946,893. On average, 17 Wall Street analysts forecast UTHR's revenue for 2027 to be $159,557,269,347, with the lowest UTHR revenue forecast at $128,104,240,194, and the highest UTHR revenue forecast at $192,241,253,757.
In 2028, UTHR is forecast to generate $184,261,267,953 in revenue, with the lowest revenue forecast at $130,608,597,441 and the highest revenue forecast at $210,153,775,083.